WO2013173392A1 - Drug-conjugates, conjugation methods, and uses thereof - Google Patents

Drug-conjugates, conjugation methods, and uses thereof Download PDF

Info

Publication number
WO2013173392A1
WO2013173392A1 PCT/US2013/041027 US2013041027W WO2013173392A1 WO 2013173392 A1 WO2013173392 A1 WO 2013173392A1 US 2013041027 W US2013041027 W US 2013041027W WO 2013173392 A1 WO2013173392 A1 WO 2013173392A1
Authority
WO
WIPO (PCT)
Prior art keywords
active agent
conjugate
pab
val
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2013/041027
Other languages
English (en)
French (fr)
Inventor
Zhenwei Miao
Yufeng Hong
Tong Zhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Concortis Biosystems Corp
Original Assignee
Concortis Biosystems Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Concortis Biosystems Corp filed Critical Concortis Biosystems Corp
Priority to EP18199921.0A priority Critical patent/EP3520817A1/en
Priority to CN201380025775.8A priority patent/CN104662000B/zh
Priority to EP13790777.0A priority patent/EP2850059A4/en
Priority to JP2015512770A priority patent/JP6239598B2/ja
Priority to US14/401,115 priority patent/US9981046B2/en
Priority to HK15108783.7A priority patent/HK1208216A1/xx
Publication of WO2013173392A1 publication Critical patent/WO2013173392A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
    • C07D207/09—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/587—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with aliphatic hydrocarbon radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms, said aliphatic radicals being substituted in the alpha-position to the ring by a hetero atom, e.g. with m >= 0, Z being a singly or a doubly bound hetero atom
    • C07D277/593—Z being doubly bound oxygen or doubly bound nitrogen, which nitrogen is part of a possibly substituted oximino radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06052—Val-amino acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids

Definitions

  • an antibody or antibody fragment such as a single-chain variable fragment
  • ADC antibody-drug conjugate
  • Some embodiments provide active agent-conjugates, methods of preparing active agent-conjugates, and uses thereof.
  • Some embodiments provide an active agent-conjugate having the structure of Formula I:
  • A is a targeting moiety
  • B is an auxiliary moiety that optionally includes a second targeting moiety, or B is null;
  • L 1 includes a group including at least one N (nitrogen) atom
  • each D is independently selected, where each D includes an active agent
  • each L 2 is independently a linker, wherein at least one L 2 links to L 1 ;
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Some embodiments provide an active agent-conjugate having the structure of Formula la:
  • A is a targeting moiety
  • B is an auxiliary moiety that optionally includes a second targeting moiety, or B is null
  • each D is independently selected, where each D includes an active agent
  • each L 2 is independently a linker
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • X is N (nitrogen) or CH
  • Y is N (nitrogen), or CH
  • m is 0, 1, or 2
  • L is a linker, or null
  • L 1A is a linker, or null.
  • Some embodiments provide an active agent-conjugate having the structure of Formula Iaa:
  • A is a targeting moiety
  • B is an auxiliary moiety that optionally includes a second targeting moiety, or B is null
  • each D is independently selected, where each D includes an active agent
  • each L 2 is independently a linker
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • X is N (nitrogen) or CH
  • L 1A is a linker, or null.
  • Some embodiments provide an active agent-conjugate having the structure of Formula lab:
  • A is a targeting moiety
  • B is an auxiliary moiety that optionally includes a second targeting moiety, or B is null
  • each D is independently selected, where each D includes an active agent
  • each L 2 is independently a linker
  • n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10
  • X is N (nitrogen) or CH
  • L 1A is a linker, or null.
  • Some embodiments provide a method of chemical synthesis comprising: reacting an amine of formula I-A with a dialdeh de of formula I-B
  • Some embodiments provide a method of chemical synthesis comprising:
  • L 1A includes -(CH 2 ) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, L 1A includes -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, L 1A includes Val-Cit-PAB, Val-Ala-PAB, Val- Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala- Ala-Asn-PAB, Ala-PAB, or PAB.
  • L 1A includes peptide, oligosaccharide, -(CH 2 ) cramp-, -(CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)- PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn- PAB, Ala-PAB, PAB, or combinations thereof.
  • the A component comprises a monoclonal antibody (mAB).
  • the A component comprises an antibody fragment, surrogate, or variant.
  • the A component comprises a protein ligand. In some embodiments, the A component comprises a protein scaffold. In some embodiments, the A component comprises a peptide. In some embodiments, the A component comprises a small molecule ligand. In some embodiments, the A component comprises at least one modified n-butyl L-a-amino acid residue.
  • L 2 includes a noncleavable unit.
  • the noncleavable unit includes -(CH 2 ) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • the noncleavable unit includes -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • L 2 includes a cleavable unit.
  • the cleavable unit comprises a peptide.
  • L 2 comprises at least one component selected from the group consisting of a peptide, an oligosaccharide, -(CH 2 )-, O (oxygen), S (sulfur), -NH-, -(CH 2 CH 2 0)-, Val, Cit, PAB, Phe, Lys, D-Val, Leu, Lys, Gly, Ala, Asn, and the like.
  • L 2 includes -(CH 2 ) literal- where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • L 2 comprises -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • L 2 comprises at least one Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala- Ala- Asn-P AB , Ala-PAB, or PAB.
  • L 2 comprises a peptide oligosaccharide, -(CH 2 ) complicat-, -(CH 2 CH 2 0) n -, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, D- Val-Leu-Lys, Gly-Gly-Arg, Ala- Ala- Asn-P AB, Ala-PAB, PAB, or combinations thereof.
  • compositions comprising an active agent- conjugate as disclosed and described herein. In some embodiments, >70% of the composition consists of no more than two active components. In some embodiments, >60% of the composition consists of no more than two active components. In some embodiments, >50% of the composition consists of no more than two active components. Some embodiments provide a composition comprising an active agent-conjugate as disclosed and described herein. In some embodiments, >70% of the composition consists of only two active components. In some embodiments, >60% of the composition consists of only two active components. In some embodiments, >50% of the composition consists of only two active components.
  • Figure 1 shows the HIC-HPLC chromatogram product of a conventional trastuzumab-emtansine two-step conjugation reaction.
  • Figure 2 shows the HIC-HPLC chromatogram product of a conventional trastuzumab-emtansine one-step conjugation reaction.
  • Figure 3 shows the HIC-HPLC chromatogram product of reacting trastuzumab and compound 34 using a conventional NHS method.
  • Figure 4 shows the HIC-HPLC chromatogram product of reacting trastuzumab and compound 34 using a selective conjugation method.
  • Figure 5 shows the HIC-HPLC chromatogram product of reacting trastuzumab and compound 67 using a selective conjugation method.
  • Figure 6 shows the HIC-HPLC chromatogram product of reacting trastuzumab and compound 62 using a selective conjugation method at a drug/antibody ratio of 1 :4.
  • Figure 7 shows the HIC-HPLC chromatogram product of reacting trastuzumab and compound 62 using a selective conjugation method at a drug/antibody ratio of 1 :6.
  • Figure 8 shows the HIC-HPLC chromatogram product of reacting trastuzumab and compound 62 using a selective conjugation method at a drug/antibody ratio of 1 :7.5.
  • Figure 9 shows the HIC-HPLC chromatogram product of reacting trastuzumab and compound 49 using a selective conjugation method.
  • Figure 10 shows the HIC-HPLC chromatogram product of reacting trastuzumab and compound 73 using a selective conjugation method.
  • Figure 11 shows a HIC-HPLC chromatogram product of reacting trastuzumab and compound 60 using a non-selective linker and a HIC-HPLC chromatogram product of reacting trastuzumab and compound 60 using an optimized linker.
  • Figure 12 shows viability of SK-BR-3 cells for a trastuzumab- compound 55 antibody-drug conjugate.
  • Figure 13 shows viability of SK-BR-3, HCC1954, MCF7, and MDA- MB-468 cells for a trastuzumab-compound 61 antibody-drug conjugate.
  • Figure 14 shows viability of SK-BR-3, HCC1954, MCF7, and MDA- MB-468 cells for a trastuzumab-compound 67 antibody-drug conjugate.
  • Figure 15 shows viability of SK-BR-3, HCC1954, MCF7, and MDA- MB-468 cells for a trastuzumab-compound 62 antibody-drug conjugate.
  • Figure 16 shows viability of SK-BR-3, HCC1954, MCF7, and MDA- MB-468 cells for a trastuzumab-compound 55 antibody-drug conjugate.
  • the active agent-conjugate is a drug-conjugate.
  • the drug-conjugate includes a targeting molecule.
  • the targeting molecule includes a monoclonal antibody (mAB).
  • the drug- conjugate includes a spacer or a multifunctional linker.
  • the spacer connects to the mAB by a group including a N (nitrogen) atom.
  • the multifunctional linker connects to the mAB by a group including a N (nitrogen) atom.
  • the spacer or multifunctional linker may be optionally connected to an auxiliary moiety.
  • the auxiliary moiety may be a second targeting molecule such as mAB and peptide.
  • the auxiliary moiety may be a hydrophilic polymer such as polyethylene glycol (PEG), and the like.
  • the spacer or multifunctional linker may include a group including a N (nitrogen) atom.
  • the spacer or multifunctional linker may include a cyclic group including a N (nitrogen) atom.
  • Conjugation methods to derivatize a polypeptide with a payload can be accomplished by forming an amide bond with a lysine side chain. Due to the presence of large number of lysine side chain amines with similar reactivity, this conjugation strategy can produce very complex heterogeneous mixtures.
  • the compositions and methods provided herein provide conjugation through lysine, where, in some embodiments, enhanced selectivity of the lysine can result in a less heterogenous mixure.
  • pharmaceutically acceptable salt refers to salts that retain the biological effectiveness and properties of a compound and, which are not biologically or otherwise undesirable for use in a pharmaceutical.
  • the compounds disclosed herein are capable of forming acid and/or base salts by virtue of the presence of amino and/or carboxyl groups or groups similar thereto.
  • Pharmaceutically acceptable acid addition salts can be formed with inorganic acids and organic acids. Inorganic acids from which salts can be derived include, for example, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, and the like.
  • Organic acids from which salts can be derived include, for example, acetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
  • Pharmaceutically acceptable base addition salts can be formed with inorganic and organic bases.
  • Inorganic bases from which salts can be derived include, for example, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum, and the like; particularly preferred are the ammonium, potassium, sodium, calcium and magnesium salts.
  • Organic bases from which salts can be derived include, for example, primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, basic ion exchange resins, and the like, specifically such as isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, and ethanolamine. Many such salts are known in the art, as described in WO 87/05297, Johnston et al, published September 11, 1987 (incorporated by reference herein in its entirety).
  • C a to C b “ or “C a _ b “ in which "a” and “b” are integers refer to the number of carbon atoms in the specified group. That is, the group can contain from “a” to “b", inclusive, carbon atoms.
  • a “Ci to C 4 alkyl” or “Ci_ 4 alkyl” group refers to all alkyl groups having from 1 to 4 carbons, that is, CH 3 -, CH 3 CH 2 - , CH 3 CH 2 CH 2 -, (CH 3 ) 2 CH-, CH 3 CH 2 CH 2 CH 2 -, CH 3 CH 2 CH(CH 3 )- and (CH 3 ) 3 C-.
  • halogen or “halo,” as used herein, means any one of the radio-stable atoms of column 7 of the Periodic Table of the Elements, e.g., fluorine, chlorine, bromine, or iodine, with fluorine and chlorine being preferred.
  • alkyl refers to a straight or branched hydrocarbon chain that is fully saturated (i.e., contains no double or triple bonds).
  • the alkyl group may have 1 to 20 carbon atoms (whenever it appears herein, a numerical range such as “1 to 20” refers to each integer in the given range; e.g., "1 to 20 carbon atoms” means that the alkyl group may consist of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 20 carbon atoms, although the present definition also covers the occurrence of the term "alkyl” where no numerical range is designated).
  • the alkyl group may also be a medium size alkyl having 1 to 9 carbon atoms.
  • the alkyl group could also be a lower alkyl having 1 to 4 carbon atoms.
  • the alkyl group may be designated as "Ci_ 4 alkyl" or similar designations.
  • Ci_ 4 alkyl indicates that there are one to four carbon atoms in the alkyl chain, i.e., the alkyl chain is selected from the group consisting of methyl, ethyl, propyl, iso-propyl, n-butyl, iso-butyl, sec-butyl, and t-butyl.
  • Typical alkyl groups include, but are in no way limited to, methyl, ethyl, propyl, isopropyl, butyl, isobutyl, tertiary butyl, pentyl, hexyl, and the like.
  • alkoxy refers to the formula -OR wherein R is an alkyl as is defined above, such as “Ci_9 alkoxy”, including but not limited to methoxy, ethoxy, n-propoxy, 1-methylethoxy (isopropoxy), n-butoxy, iso-butoxy, sec-butoxy, and tert-butoxy, and the like.
  • alkylthio refers to the formula -SR wherein R is an alkyl as is defined above, such as "Ci_g alkylthio” and the like, including but not limited to methylmercapto, ethylmercapto, n-propylmercapto, 1-methylethylmercapto (isopropylmercapto), n-butylmercapto, iso-butylmercapto, sec-butylmercapto, tert- butylmercapto, and the like.
  • alkenyl refers to a straight or branched hydrocarbon chain containing one or more double bonds.
  • the alkenyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkenyl” where no numerical range is designated.
  • the alkenyl group may also be a medium size alkenyl having 2 to 9 carbon atoms.
  • the alkenyl group could also be a lower alkenyl having 2 to 4 carbon atoms.
  • the alkenyl group may be designated as "C 2 _ 4 alkenyl" or similar designations.
  • C 2 _ 4 alkenyl indicates that there are two to four carbon atoms in the alkenyl chain, i.e., the alkenyl chain is selected from the group consisting of ethenyl, propen-l-yl, propen-2-yl, propen-3-yl, buten-l-yl, buten-2- yl, buten-3-yl, buten-4-yl, 1-methyl-propen-l-yl, 2-methyl-propen-l-yl, 1-ethyl-ethen-l- yl, 2-methyl-propen-3-yl, buta-l,3-dienyl, buta-l,2,-dienyl, and buta-l,2-dien-4-yl.
  • Typical alkenyl groups include, but are in no way limited to, ethenyl, propenyl, butenyl, pentenyl, and hexenyl, and the like.
  • alkynyl refers to a straight or branched hydrocarbon chain containing one or more triple bonds.
  • the alkynyl group may have 2 to 20 carbon atoms, although the present definition also covers the occurrence of the term "alkynyl” where no numerical range is designated.
  • the alkynyl group may also be a medium size alkynyl having 2 to 9 carbon atoms.
  • the alkynyl group could also be a lower alkynyl having 2 to 4 carbon atoms.
  • the alkynyl group may be designated as "C 2 _ 4 alkynyl" or similar designations.
  • C 2 _ 4 alkynyl indicates that there are two to four carbon atoms in the alkynyl chain, i.e., the alkynyl chain is selected from the group consisting of ethynyl, propyn-l-yl, propyn-2-yl, butyn-l-yl, butyn-3-yl, butyn-4-yl, and 2-butynyl.
  • Typical alkynyl groups include, but are in no way limited to, ethynyl, propynyl, butynyl, pentynyl, and hexynyl, and the like.
  • aromatic refers to a ring or ring system having a conjugated pi electron system and includes both carbocyclic aromatic (e.g., phenyl) and heterocyclic aromatic groups (e.g., pyridine).
  • carbocyclic aromatic e.g., phenyl
  • heterocyclic aromatic groups e.g., pyridine
  • the term includes monocyclic or fused- ring polycyclic (i.e., rings which share adjacent pairs of atoms) groups provided that the entire ring system is aromatic.
  • aryloxy and arylthio refers to RO- and RS-, in which R is an aryl as is defined above, such as “C 6 -io aryloxy” or “C 6 -io arylthio” and the like, including but not limited to phenyloxy.
  • an "aralkyl” or “arylalkyl” is an aryl group connected, as a substituent, via an alkylene group, such as "C 7-14 aralkyl” and the like, including but not limited to benzyl, 2-phenylethyl, 3-phenylpropyl, and naphthylalkyl.
  • the alkylene group is a lower alkylene group (i.e., a C 1-4 alkylene group).
  • heteroaryl refers to an aromatic ring or ring system (i.e., two or more fused rings that share two adjacent atoms) that contain(s) one or more heteroatoms, that is, an element other than carbon, including but not limited to, nitrogen, oxygen and sulfur, in the ring backbone.
  • heteroaryl is a ring system, every ring in the system is aromatic.
  • the heteroaryl group may have 5-18 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term "heteroaryl" where no numerical range is designated.
  • the heteroaryl group has 5 to 10 ring members or 5 to 7 ring members.
  • the heteroaryl group may be designated as "5-7 membered heteroaryl,” "5-10 membered heteroaryl,” or similar designations.
  • heteroaryl rings include, but are not limited to, furyl, thienyl, phthalazinyl, pyrrolyl, oxazolyl, thiazolyl, imidazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thiadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl, quinolinyl, isoquinlinyl, benzimidazolyl, benzoxazolyl, benzothiazolyl, indolyl, isoindolyl, and benzothienyl.
  • a “heteroaralkyl” or “heteroarylalkyl” is heteroaryl group connected, as a substituent, via an alkylene group. Examples include but are not limited to 2- thienylmethyl, 3-thienylmethyl, furylmethyl, thienylethyl, pyrrolylalkyl, pyridylalkyl, isoxazollylalkyl, and imidazolylalkyl.
  • the alkylene group is a lower alkylene group (i.e., a Ci_ 4 alkylene group).
  • carbocyclyl means a non-aromatic cyclic ring or ring system containing only carbon atoms in the ring system backbone.
  • carbocyclyl is a ring system, two or more rings may be joined together in a fused, bridged or spiro- connected fashion.
  • Carbocyclyls may have any degree of saturation provided that at least one ring in a ring system is not aromatic.
  • carbocyclyls include cycloalkyls, cycloalkenyls, and cycloalkynyls.
  • the carbocyclyl group may have 3 to 20 carbon atoms, although the present definition also covers the occurrence of the term "carbocyclyl” where no numerical range is designated.
  • the carbocyclyl group may also be a medium size carbocyclyl having 3 to 10 carbon atoms.
  • the carbocyclyl group could also be a carbocyclyl having 3 to 6 carbon atoms.
  • the carbocyclyl group may be designated as "C3-6 carbocyclyl" or similar designations.
  • carbocyclyl rings include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cyclohexenyl, 2,3- dihydro-indene, bicycle[2.2.2]octanyl, adamantyl, and spiro[4.4]nonanyl.
  • a "(carbocyclyl)alkyl” is a carbocyclyl group connected, as a substituent, via an alkylene group, such as "C 4 _io (carbocyclyl)alkyl” and the like, including but not limited to, cyclopropylmethyl, cyclobutylmethyl, cyclopropylethyl, cyclopropylbutyl, cyclobutylethyl, cyclopropylisopropyl, cyclopentylmethyl, cyclopentylethyl, cyclohexylmethyl, cyclohexylethyl, cycloheptylmethyl, and the like.
  • the alkylene group is a lower alkylene group.
  • cycloalkyl means a fully saturated carbocyclyl ring or ring system. Examples include cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.
  • cycloalkenyl means a carbocyclyl ring or ring system having at least one double bond, wherein no ring in the ring system is aromatic. An example is cyclohexenyl.
  • heterocyclyl means a non-aromatic cyclic ring or ring system containing at least one heteroatom in the ring backbone. Heterocyclyls may be joined together in a fused, bridged or spiro-connected fashion. Heterocyclyls may have any degree of saturation provided that at least one ring in the ring system is not aromatic. The heteroatom(s) may be present in either a non-aromatic or aromatic ring in the ring system.
  • the heterocyclyl group may have 3 to 20 ring members (i.e., the number of atoms making up the ring backbone, including carbon atoms and heteroatoms), although the present definition also covers the occurrence of the term "heterocyclyl” where no numerical range is designated.
  • the heterocyclyl group may also be a medium size heterocyclyl having 3 to 10 ring members.
  • the heterocyclyl group could also be a heterocyclyl having 3 to 6 ring members.
  • the heterocyclyl group may be designated as "3-6 membered heterocyclyl" or similar designations.
  • the heteroatom(s) are selected from one up to three of O, N or S, and in preferred five membered monocyclic heterocyclyls, the heteroatom(s) are selected from one or two heteroatoms selected from O, N, or S.
  • heterocyclyl rings include, but are not limited to, azepinyl, acridinyl, carbazolyl, cinnolinyl, dioxolanyl, imidazolinyl, imidazolidinyl, morpholinyl, oxiranyl, oxepanyl, thiepanyl, piperidinyl, piperazinyl, dioxopiperazinyl, pyrrolidinyl, pyrrolidonyl, pyrrolidionyl, 4- piperidonyl, pyrazolinyl, pyrazolidinyl, 1,3-dioxinyl, 1,3-dioxanyl, 1 ,4-dioxinyl, 1,4- dioxanyl, 1,3-oxathianyl, 1 ,4-oxathiinyl, 1 ,4-oxathianyl, 2H-l,2-oxazinyl, trioxanyl,
  • a "(heterocyclyl)alkyl” is a heterocyclyl group connected, as a substituent, via an alkylene group. Examples include, but are not limited to, imidazolinylmethyl and indolinylethyl.
  • Non- limiting examples include formyl, acetyl, propanoyl, benzoyl, and acryl.
  • R is selected from hydrogen, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C3-7 carbocyclyl, C 6 -io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
  • a "cyano" group refers to a "-CN” group.
  • a "cyanato” group refers to an "-OCN” group.
  • An "isocyanato” group refers to a "-NCO” group.
  • a "thiocyanato" group refers to a "-SCN” group.
  • An "isothiocyanato" group refers to an " -NCS” group.
  • a “sulfonyl” group refers to an "-S0 2 R” group in which R is selected from hydrogen, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C 3 _ 7 carbocyclyl, C 6 _io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
  • S-sulfonamido refers to a "-S0 2 NRARB” group in which R A and R B are each independently selected from hydrogen, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C 3 _ 7 carbocyclyl, C 6 -io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
  • N-sulfonamido refers to a "-N(R A )S0 2 R B " group in which RA and Rb are each independently selected from hydrogen, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C 3 _ 7 carbocyclyl, C 6 _io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
  • An “amino” group refers to a "-NR A R B " group in which R A and R B are each independently selected from hydrogen, Ci_ 6 alkyl, C 2 _ 6 alkenyl, C 2 _ 6 alkynyl, C 3 -7 carbocyclyl, C 6 _io aryl, 5-10 membered heteroaryl, and 5-10 membered heterocyclyl, as defined herein.
  • a non- limiting example includes free amino (i.e., -NH 2 ).
  • aminoalkyl refers to an amino group connected via an alkylene group.
  • alkoxyalkyl refers to an alkoxy group connected via an alkylene group, such as a "C 2 _g alkoxyalkyl” and the like.
  • a substituted group is derived from the unsubstituted parent group in which there has been an exchange of one or more hydrogen atoms for another atom or group.
  • a group is substituted with one or more subsitutents independently selected from Ci-C 6 alkyl, C 2 -C 6 alkenyl, C 2 -C 6 alkynyl, C3-C7 carbocyclyl (optionally substituted with halo, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkyl, and Ci-C 6 haloalkoxy), C3-C 7 -carbocyclyl-Ci-C 6 -alkyl (optionally substituted with halo, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkyl, and Ci-C 6 haloalkoxy), 5-10 membered heterocyclyl (optionally substituted with halo, Ci-C 6 alkyl, Ci-C 6 alkoxy, Ci-C 6 haloalkyl, and Ci-
  • radical naming conventions can include either a mono-radical or a di-radical, depending on the context.
  • a substituent requires two points of attachment to the rest of the molecule, it is understood that the substituent is a di-radical.
  • a substituent identified as alkyl that requires two points of attachment includes di-radicals such as -CH 2 -, - CH 2 CH 2 -, -CH 2 CH(CH 3 )CH 2 -, and the like.
  • Other radical naming conventions clearly indicate that the radical is a di-radical such as "alkylene” or "alkenylene.”
  • a substituent is depicted as a di-radical (i.e., has two points of attachment to the rest of the molecule), it is to be understood that the substituent can be attached in any directional configuration unless otherwise indicated.
  • a substituent depicted as -AE- or v 3 ⁇ 4 A ⁇ E A includes the substituent being oriented such that the A is attached at the leftmost attachment point of the molecule as well as the case in which A is attached at the rightmost attachment point of the molecule.
  • Subject as used herein, means a human or a non-human mammal, e.g., a dog, a cat, a mouse, a rat, a cow, a sheep, a pig, a goat, a non-human primate or a bird, e.g., a chicken, as well as any other vertebrate or invertebrate.
  • Isotopes may be present in the compounds described. Each chemical element present in a compound either specifically or generically described hereinmay include any isotope of said element.
  • a hydrogen atom may be explicitly disclosed or understood to be present in the compound and each such hydrogen atom is any isotope of hydrogen, including but not limited to hydrogen- 1 (protium) and hydrogen-2 (deuterium).
  • reference herein to a compound encompasses all potential isotopic forms unless the context clearly dictates otherwise.
  • Some embodiments provide a method of conjugating of a targeting molecule through a spacer or a multifunctional linker.
  • the spacer or multifunctional linker may include a group including a N (nitrogen) atom.
  • the method includes a single-step or sequential conjugation approach.
  • the drug-conjugates include a spacer or a multifunctional linker.
  • the spacer or multifunctional linker may include a noncleavable or cleavable unit such as a peptide or a disulfide bond.
  • Some embodiments provide a method of treating a patient in need thereof comprising administering an active agent-conjugate as disclosed and described herein to said patient.
  • the patient may have cancer, immune diseases, infectious diseases or metabolic diseases such as diabetes.
  • Some embodiments provide a method of diagnosis or imaging comprising administering an active agent-conjugate as disclosed and described herein to an individual.
  • A may be a targeting moiety
  • B is an auxiliary moiety that optionally includes a second targeting moiety, water soluble polymer or B is null;
  • L 1 includes a group including a N (nitrogen) atom
  • each D is independently selected, where each D includes an active agent
  • each L 2 is independently a linker, wherein at least one L 2 links to L 1 ;
  • n 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • A may be a monoclonal antibody (mAB), more specifically, A may be a human antibody, humanized antibody or a chimeric antibody.
  • mAB monoclonal antibody
  • A may be an antibody fragment, surrogate, or variant.
  • A may be a protein ligand.
  • A may be a protein scaffold. [0096] In some embodiments, A may be a peptide.
  • A may be a small molecule ligand.
  • B may be a hydrophilic polymer.
  • the hydrophilic polymer may polyethylene glycol (PEG), and the like.
  • B may be a biodegradable polymer.
  • the biodegradable polymer may be unstructured proteins polyamino acids, polypeptides polysaccharides and combinations thereof.
  • B may be a monoclonal antibody (mAB).
  • B may be an antibody fragment, surrogate, or variant.
  • B may be a protein ligand.
  • B may be a protein scaffold.
  • B may be a peptide
  • B may be R A or DNA.
  • B may be a RNA or DNA fragment.
  • B may be a small molecule ligand.
  • D may be a biologically active compound.
  • D may be a drug
  • D may be a chemotherapy drug.
  • D may be a natural product.
  • D may be an immune modulator.
  • D may be a tubulin-binder.
  • D may be a DNA-alkylating agent.
  • D may be an RNA polymerase inhibitor.
  • D may be a DNA topoisomerase inhibitor.
  • D may be an anti-epigenetic agent.
  • D may be a protein synthesis inhibitor.
  • D may be an anti-metabolism agent.
  • D may be an enzyme inhibitor.
  • D may be a peptide
  • D may be a peptidomimetic
  • D may be a siRNA
  • D may be an antisense DNA.
  • D may be a DNA intercalactor.
  • L 2 may include a spacer or a multifunctional linker. In some embodiments, L 2 may include a spacer and a multifunctional linker. In some embodiments, L 2 may include a multifunctional linker. In some embodiments, each L 2 may be a linker, wherein the linker may be cleavable or non-cleavable under biological conditions. In some embodiments, the linker may be cleavable by an enzyme. In some embodiments, L 2 may include Linker.
  • L 1 includes a cyclic group including at least one N (nitrogen) atom. In some embodiments, L 1 includes a cyclic group including at least two N (nitrogen) atoms. In some embodiments, L 1 includes a cyclic group including at least one N (nitrogen) atom and a spacer. In some embodiments, L 1 includes a cyclic group including at least two N (nitrogen) atoms and a spacer. In some embodiments, the spacer connects to the mAB by an amide bond. In some embodiments, the spacer connects to the mAB through an amine bond.
  • A comprises at least one modified n-butyl L-a- amino acid.
  • at least one modified L-Lysine residue is from an L- Lysine residue of a peptide before conjugation.
  • at least one nitrogen of L 1 is from an at least one modified n-butyl L-a-amino acid of a peptide before conjugation.
  • a and L 1 together comprise at least one modified L- Lysine residue.
  • the terminal nitrogen of the side chain of an L- Lysine residue of a peptide before conjugation is the at least one N (nitrogen) atom of L 1 .
  • A comprises the -(CH 2 ) 4 - of the side chain of an L-Lysine residue of a peptide before conjugation that provides the at least one N (nitrogen) atom of L 1 .
  • A comprises a modified n-butyl a-amino acid residue.
  • Linker may be a peptide
  • Linker may include an oligosaccharide.
  • Linker may include chitosan.
  • L 2 may include Linker and -(CH 2 ) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • L 2 may include Linker and -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Linker may include -(CH 2 ) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Linker may include -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. [0132] In some embodiments, Linker may include Val-Cit-PAB, Val-Ala- PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, Ala-PAB, PAB, D-Val-Leu- Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, or the like.
  • Linker may include any combination of peptide, oligosaccharide, -(CH 2 ) complicat-, -(CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val- Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, Ala-PAB, PAB, D-Val-Leu-Lys, Gly- Gly-Arg, Ala-Ala-Asn-PAB, and the like.
  • the spacer may include a peptide.
  • the spacer may include an oligosaccharide.
  • the spacer may include chitosan.
  • the spacer may include -(CH 2 ) endeavour- where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • L 1 may include a component including a 4-carbon bridge and -(CH 2 ) forum- where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • the spacer may include -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • L 1 may include a component including a 4-carbon bridge and -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • the spacer may include Val-Cit-PAB, Val-Ala- PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, Ala-Ala-Asn-PAB, Ala- PAB, PAB, or the like.
  • the spacer may be any combination of peptide, oligosaccharide, -(CH 2 ) complicat-, -(CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)- PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, Ala-PAB, PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, and the like.
  • L 1 may include, but is not limited to,
  • the agent-conjugate having the structure of Formula I has the structure of Formula la:
  • Y is N (nitrogen), CH- or CH-CH2-.
  • the A component comprises a monoclonal antibody (mAB). In some embodiments, the A component comprises an antibody fragment, surrogate, or variant. In some embodiments, the A component comprises a protein ligand. In some embodiments, the A component comprises a protein scaffold. In some embodiments, the A component comprises a peptide. In some embodiments, the A component comprises a small molecule ligand. In some embodiments, the A component comprises at least one modified L-Alanine residue. In some embodiments, the A component comprises at least two modified L- Alanine residues. In some embodiments, at least one L 2 includes -(CH 2 ) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • At least one L 2 includes -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • at least one L 2 includes Val-Cit-PAB, Val- Ala-PAB, Val- Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, Ala-PAB, PAB, D-Val-Leu-Lys, Gly- Gly-Arg, Ala-Ala-Asn-PAB.
  • At least one L 2 includes a peptide, an oligosaccharide, -(CH 2 ) complicat-, -(CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val-Lys(Ac)- PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, Ala-PAB, PAB, D-Val-Leu-Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, or combinations thereof.
  • the agent-conjugate having the structure of Formula I has the structure of:
  • Linker comprises at least one component selected from the group consisting a peptide, an oligosaccharide, -(CH 2 )-, O (oxygen), S (sulfur), -NH-, - (CH 2 CH 2 0)-, Val, Cit, PAB, Phe, Lys, D-Val, Leu, Lys, Gly, Ala, Asn, and the like.
  • Linker may include -(CH 2 ) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
  • Linker may include -(CH 2 CH 2 0) n - where n is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. [0151] In some embodiments, Linker may include Val-Cit-PAB, Val-Ala- PAB, Val-Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, Ala-PAB, PAB, D-Val-Leu- Lys, Gly-Gly-Arg, Ala-Ala-Asn-PAB, or the like.
  • Linker may include any combination of peptide, oligosaccharide, -(CH 2 ) complicat-, -(CH 2 CH 2 0) complicat-, Val-Cit-PAB, Val-Ala-PAB, Val- Lys(Ac)-PAB, Phe-Lys-PAB, Phe-Lys(Ac)-PAB, Ala-PAB, PAB, D-Val-Leu-Lys, Gly- Gly-Arg, Ala-Ala-Asn-PAB, and the like.
  • the agent-conjugates may include one or more components selected from the group consisting of an amino acid, an amino acid residue, an amino acid analog, and a modified amino acid.
  • targeting moiety refers to a structure that binds or associates with a biological moiety or fragment thereof.
  • the targeting moiety may be a monoclonal antibody (mAB). In some embodiments, the targeting moiety may be an antibody fragment, surrogate, or variant. In some embodiments, the targeting moiety may be a protein ligand. In some embodiments, the targeting moiety may be a protein scaffold. In some embodiments, the targeting moiety may be a peptide. In some embodiments, the targeting moiety may be RNA or DNA. In some embodiments, the targeting moiety may be a RNA or DNA fragment. In some embodiments, the targeting moiety may be a small molecule ligand.
  • mAB monoclonal antibody
  • the targeting moiety may be an antibody fragment, surrogate, or variant.
  • the targeting moiety may be a protein ligand. In some embodiments, the targeting moiety may be a protein scaffold. In some embodiments, the targeting moiety may be a peptide. In some embodiments, the targeting moiety may be RNA or DNA. In some embodiments, the targeting moiety may be a RNA or
  • the targeting moiety may be an antibody fragment described in Janthur et al., "Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice," Int. J. Mol. Sci. 2012, 13, 16020-16045, the disclosure of which is incorporated herein by reference in its entirety.
  • the targeting moiety may be an antibody fragment described in Trail, PA, "Antibody Drug Conjugates as Cancer Therapeutics," Antibodies 2013, 2, 113-129, the disclosure of which is incorporated herein by reference in its entirety.
  • the targeting moiety may be HuM195-Ac-225, HuM195-Bi-213, Anyara (naptumomab estafenatox; ABR-217620), AS1409, Zevalin (ibritumomab tiuxetan), BIIB015, BT-062, Neuradiab, CDX-1307, CR011-vcMMAE, Trastuzumab-DMl (R3502), Bexxar (tositumomab), IMGN242, IMGN388, IMGN901, 131 I-labetuzumab, IMMU-102 ( 90 Y-epratuzumab), IMMU-107 ( 90 Y-clivatuzumab tetraxetan), MDX-1203, CAT-8015, EMD 273063 (hul4.18-IL2), Tucotuzumab celmoleukin (EMD 273066; h
  • the targeting moiety may comprise, consist of, or consist essentially of the antibody portion of HuM195-Ac-225, HuM195-Bi-213, Anyara (naptumomab estafenatox; ABR-217620), AS 1409, Zevalin (ibritumomab tiuxetan), BIIB015, BT-062, Neuradiab, CDX-1307, CR011-vcMMAE, Trastuzumab- DMl (R3502), Bexxar (tositumomab), IMGN242, IMGN388, IMGN901, 131 I- labetuzumab, IMMU-102 ( 90 Y-epratuzumab), IMMU-107 ( 90 Y-clivatuzumab tetraxetan), MDX-1203, CAT-8015, EMD 273063 (hul4.18-IL2), Tucotuzumab celmoleuk
  • the targeting moiety may be Brentuximab vedotin, Trastuzumab emtansine, Inotuzumab ozogamicin, Lorvotuzumab mertansine, Glembatumumab vedotin, SAR3419, Moxetumomab pasudotox, Moxetumomab pasudotox, AGS-16M8F, AGS-16M8F, BIIB-015, BT-062, IMGN-388, or IMGN-388.
  • the targeting moiety may comprise, consist of, or consist essentially of the antibody portion of Brentuximab vedotin, Trastuzumab emtansine, Inotuzumab ozogamicin, Lorvotuzumab mertansine, Glembatumumab vedotin, SAR3419, Moxetumomab pasudotox, Moxetumomab pasudotox, AGS-16M8F, AGS-16M8F, BIIB-015, BT-062, IMGN-388, or IMGN-388.
  • the targeting moiety may comprise, consist of, or consist essentially of Brentuximab, Inotuzumab, Gemtuzumab, Milatuzumab, Trastuzumab, Glembatumomab, Lorvotuzumab, or Labestuzumab.
  • peptide refers to a structure including one or more components each individually selected from the group consisting of an amino acid, an amino acid residue, an amino acid analog, and a modified amino acid. The components are typically joined to each other through an amide bond.
  • amino acid includes naturally occurring amino acids, a molecule having a nitrogen available for forming an amide bond and a carboxylic acid, a molecule of the general formula NH 2 -CHR-COOH or the residue within a peptide bearing the parent amino acid, where "R” is one of a number of different side chains.
  • R can be a substituent found in naturally occurring amino acids.
  • R can also be a substituent referring to one that is not of the naturally occurring amino acids.
  • amino acid residue refers to the portion of the amino acid which remains after losing a water molecule when it is joined to another amino acid.
  • amino acid analog refers to a structural derivative of an amino acid parent compound that often differs from it by a single element.
  • modified amino acid refers to an amino acid bearing an "R” substituent that does not correspond to one of the twenty genetically coded amino acids.
  • the abbreviations for the genetically encoded L- enantiomeric amino acids are conventional and are as follows:
  • amino acid residues in the active agent-conjugate can be replaced with other amino acid residues without significantly deleteriously affecting, and in many cases even enhancing, the activity of the peptides.
  • altered or mutated forms of the active agent-conjugate wherein at least one defined amino acid residue in the structure is substituted with another amino acid residue or derivative and/or analog thereof. It will be recognized that in preferred embodiments, the amino acid substitutions are conservative, i.e., the replacing amino acid residue has physical and chemical properties that are similar to the amino acid residue being replaced.
  • the amino acids can be conveniently classified into two main categories—hydrophilic and hydrophobic—depending primarily on the physical-chemical characteristics of the amino acid side chain. These two main categories can be further classified into subcategories that more distinctly define the characteristics of the amino acid side chains.
  • hydrophilic amino acids can be further subdivided into acidic, basic and polar amino acids.
  • hydrophobic amino acids can be further subdivided into nonpolar and aromatic amino acids.
  • the definitions of the various categories of amino acids are as follows:
  • hydrophilic amino acid refers to an amino acid exhibiting a hydrophobicity of less than zero according to the normalized consensus hydrophobicity scale of Eisenberg et al, 1984, J. Mol. Biol. 179: 125-142. Genetically encoded hydrophilic amino acids include Thr (T), Ser (S), His (H), Glu (E), Asn (N), Gin (Q), Asp (D), Lys (K) and Arg (R).
  • hydrophobic amino acid refers to an amino acid exhibiting a hydrophobicity of greater than zero according to the normalized consensus hydrophobicity scale of Eisenberg, 1984, J. Mol. Biol. 179:1.25-142. Genetically encoded hydrophobic amino acids include Pro (P), He (I), Phe (F), Val (V), Leu (L), Trp (W), Met (M), Ala (A), Gly (G) and Tyr (Y).
  • acidic amino acid refers to a hydrophilic amino acid having a side chain pK value of less than 7. Acidic amino acids typically have negatively charged side chains at physiological pH due to loss of a hydrogen ion. Genetically encoded acidic amino acids include Glu (E) and Asp (D).
  • basic amino acid refers to a hydrophilic amino acid having a side chain pK value of greater than 7.
  • Basic amino acids typically have positively charged side chains at physiological pH due to association with hydronium ion.
  • Genetically encoded basic amino acids include His (H), Arg (R) and Lys (K).
  • polar amino acid refers to a hydrophilic amino acid having a side chain that is uncharged at physiological pH, but which has at least one bond in which the pair of electrons shared in common by two atoms is held more closely by one of the atoms.
  • Genetically encoded polar amino acids include Asn (N), Gin (Q) Ser (S) and Thr (T).
  • nonpolar amino acid refers to a hydrophobic amino acid having a side chain that is uncharged at physiological pH and which has bonds in which the pair of electrons shared in common by two atoms is generally held equally by each of the two atoms (i.e., the side chain is not polar).
  • Genetically encoded nonpolar amino acids include Leu (L), Val (V), lie (I), Met (M), Gly (G) and Ala (A).
  • aromatic amino acid refers to a hydrophobic amino acid with a side chain having at least one aromatic or heteroaromatic ring.
  • the aromatic or heteroaromatic ring may contain one or more substituents such as—OH,— SH,— CN,— F,—CI,—Br,—I,— N0 2 ,—NO,— NH 2 ,— NHR,— NRR,— C(0)R,— C(0)OH,— C(0)OR,— C(0)NH 2 ,— C(0)NHR,— C(0)NRR and the like where each R is independently (Ci - C 6 ) alkyl, substituted (Ci - C 6 ) alkyl, (Ci - C 6 ) alkenyl, substituted (Ci - C 6 ) alkenyl, (Ci - C 6 ) alkynyl, substituted (Ci - C 6 ) alkynyl, (C 5 - C 2 o) aryl
  • aliphatic amino acid refers to a hydrophobic amino acid having an aliphatic hydrocarbon side chain. Genetically encoded aliphatic amino acids include Ala (A), Val (V), Leu (L) and lie (I).
  • Cys (C) is unusual in that it can form disulfide bridges with other Cys (C) residues or other sulfanyl-containing amino acids.
  • the ability of Cys (C) residues (and other amino acids with— SH containing side chains) to exist in a peptide in either the reduced free — SH or oxidized disulfide-bridged form affects whether Cys (C) residues contribute net hydrophobic or hydrophilic character to a peptide.
  • Cys (C) exhibits a hydrophobicity of 0.29 according to the normalized consensus scale of Eisenberg (Eisenberg, 1984, supra), it is to be understood that for purposes of the preferred embodiments Cys (C) is categorized as a polar hydrophilic amino acid, notwithstanding the general classifications defined above.
  • amino acids having side chains exhibiting two or more physical-chemical properties can be included in multiple categories.
  • amino acid side chains having aromatic moieties that are further substituted with polar substituents, such as Tyr (Y) may exhibit both aromatic hydrophobic properties and polar or hydrophilic properties, and can therefore be included in both the aromatic and polar categories.
  • polar substituents such as Tyr (Y)
  • the amino acid substitutions need not be, and in certain embodiments preferably are not, restricted to the genetically encoded amino acids.
  • the active agent-conjugate may contain genetically non-encoded amino acids.
  • amino acid residues in the active agent-conjugate may be substituted with naturally occurring non-encoded amino acids and synthetic amino acids.
  • Certain commonly encountered amino acids which provide useful substitutions for the active agent-conjugates include, but are not limited to, ⁇ -alanine ( ⁇ - Ala) and other omega-amino acids such as 3-aminopropionic acid, 2,3-diaminopropionic acid (Dpr), 4-aminobutyric acid and so forth; a-aminoisobutyric acid (Aib); ⁇ - aminohexanoic acid (Ahx); ⁇ -aminovaleric acid (Ava); N-methylglycine or sarcosine (MeGly); ornithine (Orn); citrulline (Cit); t-butylalanine (t-BuA); t-butylglycine (t-BuG); N-methylisoleucine (Melle); phenylglycine (Phg); cyclohexylalanine (Cha); norleucine (Nle); naphthylalanine (Nal); 4-phen
  • Aromatic F Y, W Phg, Nal, Thi, Tic, Phe (4-Cl), Phe (2-F),
  • the amino acids of the active agent-conjugate will be substituted with L-enantiomeric amino acids, the substitutions are not limited to L-enantiomeric amino acids.
  • the peptides may advantageously be composed of at least one D-enantiomeric amino acid. Peptides containing such D-amino acids are thought to be more stable to degradation in the oral cavity, gut or serum than are peptides composed exclusively of L-amino acids.
  • the compositions and method provided herein can provide an increased selectivity in targeting lysine side chain amino groups.
  • >80% of a composition comprising an active agent-conjugate as disclosed and described herein consists of no more than two active components.
  • >70% of a composition comprising an active agent-conjugate as disclosed and described herein consists of no more than two active components.
  • >60% of a composition comprising an active agent-conjugate as disclosed and described herein consists of no more than two active components.
  • >50% of a composition comprising an active agent-conjugate as disclosed and described herein consists of no more than two active components.
  • >40% of a composition comprising an active agent-conjugate as disclosed and described herein consists of no more than two active components. In some embodiments >30% of a composition comprising an active agent-conjugate as disclosed and described herein consists of no more than two active components. In some embodiments >80% of a composition comprising an active agent-conjugate as disclosed and described herein consists of only two active components. In some embodiments >70% of a composition comprising an active agent-conjugate as disclosed and described herein consists of only two active components. In some embodiments >60% of a composition comprising an active agent-conjugate as disclosed and described herein consists of only two active components.
  • >50% of a composition comprising an active agent-conjugate as disclosed and described herein consists of only two active components. In some embodiments >40% of a composition comprising an active agent-conjugate as disclosed and described herein consists of only two active components. In some embodiments >30% of a composition comprising an active agent- conjugate as disclosed and described herein consists of only two active components.
  • activated carboxylic components were selected, not limited from the following group to provide active agent-conjugates of Formula I according to General Conjugation Procedure II:
  • active agent-conjugates of Formula I made according to General Conjugation Procedure II have, but are not limited to, the following structures:
  • Conjugation method A Conjugation on Lys residues via an activated cylic carboxylic acid
  • a cyclic carboxylic acid moiety can also be easily obtained from the linear carboxylic acid derivative if the cyclic acid is not directly installed. For example:
  • Conjugation method B Conjugation on Lys residues via an activated cylic carboxylic acid
  • Method 1-1 Linker and Drug connected via a carbamate bond. The following general procedures were employed:
  • Method 1-3 Active molecule containing a carboxylic acid moiety connected to an alkoxyamino linker via formation of hydoxamate (General procedure A or B), followed by removal of protective groups.
  • Method 2-2 Compounds beariung free amino group to react with a di-acid to introduce carboxylic acid (General procedure B).
  • Th ialdehyde carboxylic acid was synthesized according to the following scheme:
  • Step 3 Introducing the final functional groups prior to conjugation
  • the carboxylic acid can be activated using a variety of methods to afford an activated form.
  • the carboxylic acid can be activated using the following methods: A) Tetrahedron 61 (2005) 10827-10852; B) Beckwith, A. L. J. In The Chemistry of Amides; Zabicky, J., Ed.; Synthesis of Amides; Interscience: London, 1970; pp 105-109; C) Handbook of Reagents for Organic Synthesis: Activating Agents and Protecting Groups; Pearson, A. J., Roush, W. R., Eds.; Wiley: New York, 1999; pp 370- 373; D) Lloyd- Williams, P., Albericio, F., and Giralt, E.
  • amino acid sulfonamide derivatives 11 were synthesized according to previously reported procedure (AR IVOC 2004 (xii) 14-22, or WO 2007146695) using Boc protected amino acid and cyclopropyl/methyl sulfonamide, followed by removal of Boc (General procedure C)
  • Compound 13 was synthesized using the general procedures described above as following: DIC/HOAt mediated amide bond formation (General procedure B) between Boc-N-Me-Val-Val-Dil-Dap-OH (compound 1) and amine 1 1 , followed by removal of Boc (General procedure C). The final compound was purified by reverse phase HPLC to give compound 13 as a white powder after lyophilization. MS m/z Calcd for C 42 H 70 N 6 O 9 S 834.5, Found 835.6 ([M+H] + ).
  • amino acid sulfonamide derivatives 14 were synthesized according to previously reported procedure (AR IVOC 2004 (xii) 14-22, or WO 2007146695) using Boc protected amino acid and cyclopropyl/methyl sulfonamide, followed by removal of Boc (General procedure C).
  • Compound 16 was synthesized using the general procedures described above as following: DIC/HOAt mediated amide bond formation (General procedure B) between Boc-N-Me-Val-Val-Dil-Dap-OH (compound 10) and amine 14, followed by removal of Boc (General procedure C). The final compound was purified by reverse phase HPLC to give compound 16 as a white powder after lyophilization. MS m/z Calcd for C 41 H 70 N 6 O 10 S 838.5, Found 839.6 ([M+H] + ).
  • Compound 32 was synthesized using the general procedures described above as following: DIC/HOAt mediated amide bond formation (General procedure B) between Auristatin F and compound 24, followed by removal of Fmoc (General procedure D), reaction with glutaric anhydride (General procedure H), and conversion of the acid to the corresponding NHS ester (General procedure J).
  • Compound 48 was synthesized using the general procedures described above as following: Carbamate formation (General procedure I) between compound 13 and Fmoc-VC-PAB-PNP, followed by removal of Fmoc (General procedure D) to give the intermediate compound 47 which was converted to the final compound using the same procedure described for the synthesis of compound 34. The final compound was purified by reverse phase HPLC to give compound 48 as a white powder after lyophilization. MS m/z Calcd for 1450.8, Found 1451.7 ([M+H] + ).
  • Compound 60 was synthesized using the general procedures described above as following: HATU mediated amide bond formation (General procedure A) between compound 59 and methyl isonipecotate, followed by saponification to remove methyl group from ester (General procedure F). The final compound was purified by reverse phase HPLC to give compound 60 as a white powder after lyophilization. MS m/z Calcd for C 5 iH 83 N 7 0i 3 S 1033.6, Found 1034.7 ([M+H] + ).
  • Compound 85 was synthesized using the general procedures described above as following: DIC/HOAt mediated amide bond formation (General procedure B) between compound 83 and acid 86.
  • the intermediate 84 was purified by RP-HPLC and the obtained pure product was treated with IN aq. HC1 (20 eq) in acetonitrile/water (6/4, v/v) for 1 h. The crude was used directly without further purification. MS found: 1136.6 (M+H) + .
  • Figure 1 shows the HIC-HPLC chromatogram product of the trastuzumab-emtansine two-step conjugation reaction, where DAR represents the number of drugs conjugated per antibody, based on UV252 and UV280.
  • trastuzumab and emtansine were conjugated using a conventional one-step method under conditions provided in U.S. Pat. No. 8,435,528 and references cited therein.
  • the product of the trastuzumab-emtansine one-step conjugation reaction was analyzed using HIC-HPLC, as depicted in Figure 2.
  • trastuzumab and compound 34 were conjugated using a conventional NHS method under conditions provided in U.S. Pat. No. 8,435,528 and references cited therein.
  • the product of the trastuzumab-compound 34 NHS conjugation reaction was analyzed using HIC-HPLC, as depicted in Figure 3.
  • trastuzumab and compound 34 were conjugated using a selective conjugation method under General Conjugation Procedure II. Samples were removed after reaction for 20 hours and for 40 hours. The product of the trastuzumab-compound 34 selective conjugation reaction was analyzed using HIC-HPLC, as depicted in Figure 4. The number of drugs conjugated per antibody (DAR) were primarily 0, 1 and 2, as depicted in Figure 4.
  • DAR drugs conjugated per antibody
  • Trastuzumab and compound 67 were conjugated using a selective conjugation method under the General Conjugation Procedure II. The product of the trastuzumab-compound 67 selective conjugation reaction was analyzed using HIC-HPLC, as depicted in Figure 5.
  • trastuzumab and compound 62 were conjugated using a selective conjugation method under the General Conjugation Procedure II, where the ratio of compound 62 to trastuzumab used in the conjugation reaction was 1 :4.
  • the product of the trastuzumab-compound 62 selective conjugation reaction was analyzed using HIC- HPLC, as depicted in Figure 6.
  • the number of drugs conjugated per antibody (DAR) for DAR 0, 1, and 2 were 0 (4%), 1 (29%) and 2 (45%), as depicted in Figure 6.
  • trastuzumab and compound 62 were conjugated using a selective conjugation method under the General Conjugation Procedure II, where the ratio of compound 62 to trastuzumab used in the conjugation reaction was 1 :6.
  • the product of the trastuzumab-compound 62 selective conjugation reaction was analyzed using HIC- HPLC, as depicted in Figure 7.
  • the number of drugs conjugated per antibody (DAR) for DAR 0, 1, and 2 were 0 (3%), 1 (26%) and 2 (47%), as depicted in Figure 7.
  • trastuzumab and compound 62 were conjugated using a selective conjugation method under the General Conjugation Procedure II, where the ratio of compound 62 to trastuzumab used in the conjugation reaction was 1 :7.5.
  • the product of the trastuzumab-compound 62 selective conjugation reaction was analyzed using HIC- HPLC, as depicted in Figure 8.
  • the number of drugs conjugated per antibody (DAR) for DAR 0, 1, and 2 were 0 (1%), 1 (18%) and 2 (46%), as depicted in Figure 8.
  • trastuzumab and compound 49 were conjugated using a selective conjugation method under the General Conjugation Procedure II.
  • the product of the trastuzumab-compound 49 selective conjugation reaction was analyzed using HIC-HPLC, as depicted in Figure 9.
  • the number of drugs conjugated per antibody (DAR) for DAR 0, 1, and 2 were 0 (11%), 1 (26%) and 2 (45%), as depicted in Figure 9.
  • trastuzumab and compound 73 were conjugated using a selective conjugation method under the General Conjugation Procedure II.
  • the product of the trastuzumab-compound 73 selective conjugation reaction was analyzed using HIC-HPLC, as depicted in Figure 10.
  • the number of drugs conjugated per antibody (DAR) for DAR 0, 1, and 2 are depicted in Figure 10.
  • Trastuzumab and compound 60 were conjugated using a conventional NHS method.
  • the product of the trastuzumab-compound 60 conjugated with the nonselective linker was analyzed using HIC-HPLC, as depicted in Figure 11. As seen in Figure 11, no major ADC peaks were observed when using the non-selective linker.
  • trastuzumab and compound 60 were conjugated using the selective conjugation method under the General Conjugation Procedure II.
  • the product of the trastuzumab-compound 60 conjugated with the optimized linker was analyzed using HIC- HPLC, as depicted in Figure 11. As seen in Figure 11, two major ADC peaks were observed when using the optimized linker.
  • Antibody drug conjugates were the analyzed for cytotoxicity.
  • the cell lines used were SK-BR-3 human breast adenocarcinoma (HER2 triple positive), HCC1954 human Ductal Carcinoma (HER2 triple positive), MCF7 human breast adenocarcinoma (HER2 normal), and MDA-MB-468 human breast adenocarcinoma (HER2 negative). These cells were available from ATCC.
  • SK-BR-3 cells were grown in McCoy's 5 A medium (Caisson Labs, North Logan, UT) supplemented with 10% fetal bovine serum.
  • HCC1954 cells were grown in RPMI-1640 medium (Caisson Labs, North Logan, UT) supplemented with 10% fetal bovine serum.
  • MCF7 and MDA-MB-468 cells were grown in DMEM/F12 medium (Caisson Labs, North Logan, UT) supplemented with 10% fetal bovine serum.
  • SK-BR-3, MCF7, and MDA-MB-468 cells were plated in 96- well plates at approximately 7,500 cells/well, and HCC1954 cells were plated in 96-well plates at approximately 20,000 cells/well.
  • Compounds or the antibody-drug conjugates were added in duplicates in the same day. After 72 hour incubation at 37°C, CellTiter-Glo (Promega, Madison, WI) were added and cell viability was determined as describe by the manufacture's protocol. The percent viability was determined as following:
  • % Viability Average Luminescence Value of the duplicates (treated wells) / Average Luminescence Value of the untreated wells
  • trastuzumab and compound 55 were conjugated using a selective conjugation method under the General Conjugation Procedure II.
  • the product of the trastuzumab-compound 55 selective conjugation reaction was analyzed for cytotoxicity on SK-BR-3 cells, as depicted in Figure 12.
  • Trastuzumab and compound 61 were conjugated using a selective conjugation method under the General Reaction Conditions General Conjugation Procedure II.
  • the product of the trastuzumab-compound 61 selective conjugation reaction was analyzed for cytotoxicity on SK-BR-3, HCC1954, MCF7, and MDA-MB- 468 cells, as depicted in Figure 13.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
PCT/US2013/041027 2012-05-15 2013-05-14 Drug-conjugates, conjugation methods, and uses thereof Ceased WO2013173392A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP18199921.0A EP3520817A1 (en) 2012-05-15 2013-05-14 Drug-conjugates, conjugation methods, and uses thereof
CN201380025775.8A CN104662000B (zh) 2012-05-15 2013-05-14 药物偶联物及其偶联方法和用途
EP13790777.0A EP2850059A4 (en) 2012-05-15 2013-05-14 CONJUGATES OF MEDICATION, METHODS OF CONJUGATION AND USE THEREOF
JP2015512770A JP6239598B2 (ja) 2012-05-15 2013-05-14 薬物複合体、複合体形成方法、およびその使用
US14/401,115 US9981046B2 (en) 2012-05-15 2013-05-14 Drug-conjugates, conjugation methods, and uses thereof
HK15108783.7A HK1208216A1 (en) 2012-05-15 2013-05-14 Drug-conjugates, conjugation methods, and uses thereof

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
US201261647300P 2012-05-15 2012-05-15
US61/647,300 2012-05-15
US201261648406P 2012-05-17 2012-05-17
US201261648532P 2012-05-17 2012-05-17
US61/648,406 2012-05-17
US61/648,532 2012-05-17
US201261652512P 2012-05-29 2012-05-29
US61/652,512 2012-05-29

Publications (1)

Publication Number Publication Date
WO2013173392A1 true WO2013173392A1 (en) 2013-11-21

Family

ID=49584226

Family Applications (3)

Application Number Title Priority Date Filing Date
PCT/US2013/041027 Ceased WO2013173392A1 (en) 2012-05-15 2013-05-14 Drug-conjugates, conjugation methods, and uses thereof
PCT/US2013/041026 Ceased WO2013173391A1 (en) 2012-05-15 2013-05-14 Drug-conjugates, conjugation methods, and uses thereof
PCT/US2013/041028 Ceased WO2013173393A1 (en) 2012-05-15 2013-05-14 Drug-conjugates, conjugation methods, and uses thereof

Family Applications After (2)

Application Number Title Priority Date Filing Date
PCT/US2013/041026 Ceased WO2013173391A1 (en) 2012-05-15 2013-05-14 Drug-conjugates, conjugation methods, and uses thereof
PCT/US2013/041028 Ceased WO2013173393A1 (en) 2012-05-15 2013-05-14 Drug-conjugates, conjugation methods, and uses thereof

Country Status (7)

Country Link
US (7) US9981046B2 (https=)
EP (6) EP3590541B1 (https=)
JP (5) JP6280103B2 (https=)
CN (4) CN104640572B (https=)
ES (2) ES2734259T3 (https=)
HK (1) HK1208216A1 (https=)
WO (3) WO2013173392A1 (https=)

Cited By (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
WO2016005593A1 (en) 2014-07-11 2016-01-14 Genmab A/S Antibodies binding axl
WO2016041082A1 (en) 2014-09-17 2016-03-24 CDRD Ventures, Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2017009258A1 (en) 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US9662402B2 (en) 2012-10-16 2017-05-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US20170190736A1 (en) * 2015-01-28 2017-07-06 Sorrento Therapeutics, Inc. Antibody Drug Conjugates
JP2017530100A (ja) * 2014-09-11 2017-10-12 シアトル ジェネティックス， インコーポレイテッド 第３級アミン含有薬物物質の標的送達
US9801951B2 (en) 2012-05-15 2017-10-31 Concortis Biosystems, Corp. Drug-conjugates, conjugation methods, and uses thereof
US9943610B2 (en) 2012-12-21 2018-04-17 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
US9968683B2 (en) 2014-12-17 2018-05-15 Organolinx Corp. Method for conjugating molecules
US10017460B2 (en) 2013-06-12 2018-07-10 Organolinx Corp. Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof
KR20180080128A (ko) * 2015-11-23 2018-07-11 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-ErbB2 항체-약물 접합체 및 그 조성물, 제조 방법 및 용도
EP3253212A4 (en) * 2015-02-06 2018-09-19 Sorrento Therapeutics, Inc. Antibody drug conjugates
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
EP3412315A4 (en) * 2016-02-04 2019-09-11 Zhejiang Zova Biotherapeutics Inc. ANTI-HER2 ANTIBODY ACTIVE CONJUGATE AND ITS USE
US10434185B2 (en) 2017-01-20 2019-10-08 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
US10500204B2 (en) 2007-06-25 2019-12-10 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
EP3471771A4 (en) * 2016-05-31 2020-04-15 Sorrento Therapeutics, Inc. ANTIBODY-MEDICINE CONJUGATES WITH DERIVATIVES OF AMATOXIN AS A MEDICINAL PRODUCT
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
US10647676B2 (en) 2004-07-23 2020-05-12 Endocyte, Inc. Bivalent linkers and conjugates thereof
US10675355B2 (en) 2013-12-27 2020-06-09 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
US10738086B2 (en) 2007-06-25 2020-08-11 Endocyte Inc. Conjugates containing hydrophilic spacer linkers
US10835616B2 (en) 2014-10-14 2020-11-17 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
US11103593B2 (en) 2013-10-15 2021-08-31 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11389543B2 (en) 2017-09-08 2022-07-19 Seagen Inc. Process for the preparation of tubulysins and intermediates thereof
WO2022197945A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11844839B2 (en) 2016-03-25 2023-12-19 Seagen Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
WO2024179381A1 (zh) 2023-02-28 2024-09-06 四川科伦博泰生物医药股份有限公司 一类化学偶联连接子及其用途

Families Citing this family (107)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
WO2015113760A1 (en) * 2014-01-28 2015-08-06 Tube Pharmaceuticals Gmbh Cytotoxic tubulysin compounds for conjugation
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
GB201402006D0 (en) 2014-02-06 2014-03-26 Oncomatryx Biopharma S L Antibody-drug conjugates and immunotoxins
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
WO2015183978A1 (en) * 2014-05-28 2015-12-03 Agensys, Inc. Derivatives of dolaproine-dolaisoleuine peptides
US10077287B2 (en) 2014-11-10 2018-09-18 Bristol-Myers Squibb Company Tubulysin analogs and methods of making and use
BR112017012042A2 (pt) * 2014-12-08 2018-01-16 Sorrento Therapeutics Inc composição de conjugado anticorpo-droga e método para tratar câncer de mama
WO2016127790A1 (zh) * 2015-02-15 2016-08-18 江苏恒瑞医药股份有限公司 配体-细胞毒性药物偶联物、其制备方法及其应用
CN106279352B (zh) * 2015-05-29 2020-05-22 上海新理念生物医药科技有限公司 海兔毒素10的衍生物及其应用
CN106243127B (zh) 2015-06-09 2021-01-26 凯惠科技发展(上海)有限公司 抗体药物偶联物、中间体、制备方法、药物组合物及应用
NZ739830A (en) 2015-07-12 2021-12-24 Hangzhou Dac Biotech Co Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
WO2017054080A1 (en) * 2015-09-29 2017-04-06 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
WO2017058808A1 (en) * 2015-10-02 2017-04-06 Sirenas Llc Anti-cancer compounds and conjugates thereof
CN107029242A (zh) 2015-11-03 2017-08-11 财团法人工业技术研究院 抗体药物复合物及其制造方法
PE20231050A1 (es) 2016-03-02 2023-07-11 Eisai Randd Man Co Ltd Conjugados de anticuerpo y farmaco basados en eribulina y metodos para su uso
WO2017172907A1 (en) * 2016-03-29 2017-10-05 Sorrento Therapeutics, Inc. Calicheamicin antibody drug conjugates linking an amidoacetyl group to a sugar moiety on calicheamicin
CN108779146B (zh) * 2016-03-29 2022-03-18 东丽株式会社 肽衍生物及其用途
JP2019513371A (ja) 2016-04-01 2019-05-30 アビディティー バイオサイエンシーズ エルエルシー 核酸ポリペプチド組成物とその使用
WO2018036438A1 (zh) * 2016-08-23 2018-03-01 四川科伦博泰生物医药股份有限公司 一种抗体-药物偶联物及其制备方法和应用
CA3044898C (en) * 2016-11-25 2022-04-05 Mabwell (shanghai) Bioscience Co., Ltd. Di-substituted maleic amide linker for antibody-drug conjugating and preparation method and use thereof
CN108101825B (zh) * 2016-11-25 2022-02-22 迈威(上海)生物科技股份有限公司 用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途
CN109810039B (zh) * 2017-11-22 2021-11-12 迈威(上海)生物科技股份有限公司 一种用于抗体-药物偶联的双取代马来酰胺类连接子及其制备方法和用途
US10864279B2 (en) 2016-12-16 2020-12-15 Industrial Technology Research Institute Linker-drug and antibody-drug conjugate (ADC) employing the same
MX2019008199A (es) 2017-01-06 2019-11-25 Avidity Biosciences Llc Composiciones de acido nucleico polipeptido y metodos de induccion de la omision de exon.
KR20210122319A (ko) * 2017-04-06 2021-10-08 항저우 디에이씨 바이오테크 씨오, 엘티디 비스-링키지를 사용한 세포독성 약물의 접합
WO2018192407A1 (zh) 2017-04-19 2018-10-25 四川科伦博泰生物医药股份有限公司 细胞毒素和偶联物、其用途和制备方法
CA3067572A1 (en) 2017-06-20 2018-12-27 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
KR20200016874A (ko) 2017-06-20 2020-02-17 마드리갈 파마슈티칼스 인코포레이티드 표적화 치료제를 포함하는 병용 요법
EP3641831B1 (en) * 2017-06-20 2024-11-06 Sorrento Therapeutics, Inc. Cd38 antibody drug conjugate
GB201711809D0 (en) 2017-07-21 2017-09-06 Governors Of The Univ Of Alberta Antisense oligonucleotide
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
US10799598B2 (en) 2017-08-01 2020-10-13 Sorrento Therapeutics, Inc. Disulfide bridging conjugates
EP4321523A3 (en) 2017-08-10 2024-04-24 Sumitomo Pharma Co., Ltd. Hemiasterlin derivatives and antibody-drug conjugates including same
EP3691657A4 (en) 2017-10-04 2021-07-21 Avidity Biosciences, Inc. NUCLEIC ACID POLYPEPTIDE COMPOSITIONS AND USES THEREOF
KR102762352B1 (ko) * 2017-11-30 2025-02-05 씨젠 인크. 약물 링커 화합물의 제조방법
AU2018378812B2 (en) 2017-12-06 2025-05-22 Avidity Biosciences, Inc. Compositions and methods of treating muscle atrophy and myotonic dystrophy
CN119241554A (zh) 2017-12-15 2025-01-03 四川科伦博泰生物医药股份有限公司 生物活性物偶联物及其制备方法和用途
WO2019149116A1 (zh) * 2018-01-30 2019-08-08 四川科伦博泰生物医药股份有限公司 制备偶联物的方法
SG11202007540SA (en) * 2018-02-20 2020-09-29 Seattle Genetics Inc Hydrophobic auristatin f compounds and conjugates thereof
CN119405832A (zh) 2018-06-01 2025-02-11 卫材R&D管理有限公司 剪接调节抗体-药物缀合物及其使用方法
EP3801523B1 (en) 2018-06-01 2024-09-11 Eisai R&D Management Co., Ltd. Splicing modulators
US20210276971A1 (en) 2018-06-20 2021-09-09 The Research Foundation For The State University Of New York Triazamacrocycle-derived chelator compositions for coordination of imaging and therapy metal ions and methods of using same
IL282182B2 (en) * 2018-10-12 2025-09-01 Hangzhou Dac Biotech Co Ltd Cytotoxic drug conjugates with a bis linkage
US12583932B2 (en) 2018-11-16 2026-03-24 Virtuoso Binco, Inc. CD38 and ICAM1 antibodies and uses thereof
SG11202102419VA (en) 2018-12-13 2021-04-29 Eisai R&D Man Co Ltd Herboxidiene splicing modulator antibody-drug conjugates and methods of use
IL312067B2 (en) 2018-12-21 2025-08-01 Avidity Biosciences Inc Anti-transferrin receptor antibodies and uses thereof
AU2019403552A1 (en) * 2018-12-21 2021-06-17 Seagen Inc. ADCs with thiol multiplex linkers
WO2020160156A2 (en) 2019-01-30 2020-08-06 Immutics, Inc. Anti-gal3 antibodies and uses thereof
WO2020166592A1 (ja) 2019-02-13 2020-08-20 大日本住友製薬株式会社 ヘミアスタリン誘導体とその抗体薬物複合体
JP7432531B2 (ja) 2019-02-13 2024-02-16 住友ファーマ株式会社 システイン残基を有するヘミアスタリン誘導体
CN109824759A (zh) * 2019-03-08 2019-05-31 联宁（苏州）生物制药有限公司 一种用于抗体药物偶联物的药物-连接子mc-mmaf的制备方法及其中间体
WO2020219820A1 (en) 2019-04-25 2020-10-29 Avidity Biosciences, Inc. Nucleic acid compositions and methods of multi-exon skipping
US12006499B2 (en) 2019-06-06 2024-06-11 Avidity Biosciences, Inc. Una amidites and uses thereof
CN114375296A (zh) 2019-06-06 2022-04-19 艾维迪提生物科学公司 核酸多肽组合物及其用途
JP7835441B2 (ja) 2019-12-06 2026-03-25 トゥルーバインディング，インコーポレイテッド Ｇａｌ３とインスリン受容体又はインテグリンとの相互作用を妨害する抗体及びそれらの使用方法
CN115666656A (zh) 2020-01-13 2023-01-31 西纳福克斯股份有限公司 通过环加成双侧功能化抗体
JP7807375B2 (ja) 2020-01-13 2026-01-27 シンアフィックス ビー．ブイ． 付加環化を介して両側官能化された抗体
WO2021144315A1 (en) 2020-01-13 2021-07-22 Synaffix B.V. Conjugates of antibodies an immune cell engagers
CA3168986A1 (en) 2020-02-26 2021-09-02 Sorrento Therapeutics, Inc. Activatable antigen binding proteins with universal masking moieties
FR3107648B1 (fr) * 2020-02-27 2022-03-18 Mc Saf conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
KR20220151166A (ko) * 2020-03-09 2022-11-14 시그마-알드리치 컴퍼니., 엘엘씨 중간체 공통 중간체를 통한 돌라스타틴 및 아우리스타틴 유사체의 효율적인 제조
WO2021188390A1 (en) 2020-03-19 2021-09-23 Avidity Biosciences, Inc. Compositions and methods of treating facioscapulohumeral muscular dystrophy
SI4126066T1 (sl) 2020-03-27 2026-04-30 Avidity Biosciences, Inc. Sestavki in postopki zdravljenja mišične distrofije
US10987487B1 (en) 2020-04-29 2021-04-27 Cure Medical Llc Gripper sleeve for urinary catheter
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
AU2021284401A1 (en) 2020-06-05 2023-01-05 Eisai R&D Management Co., Ltd. Anti-BCMA antibody-drug conjugates and methods of use
EP4172141A1 (en) 2020-06-26 2023-05-03 Synaffix B.V. Methods for the preparation of linker payload constructs
NL2026400B1 (en) 2020-09-02 2022-05-04 Synaffix Bv Methods for the preparation of bioconjugates
EP4208259A2 (en) 2020-09-04 2023-07-12 NovaRock Biotherapeutics, Ltd. Nectin-4 antibodies and uses thereof
JP2023541637A (ja) 2020-09-15 2023-10-03 シンアフィックス ビー．ブイ． 抗体－エクサテカンコンジュゲート
NL2026947B1 (en) 2020-11-20 2022-07-01 Synaffix Bv Tyrosine-based antibody conjugates
UY39587A (es) 2020-12-23 2022-07-29 Univ Muenchen Ludwig Maximilians Conjugados anticuerpo-droga mejorados dirigidos contra cd30 y usos de los mismos
CA3198230A1 (en) * 2021-01-28 2022-08-04 Jian Chen Conjugate and use thereof
JP2024506022A (ja) 2021-02-08 2024-02-08 シンアフィックス ビー．ブイ． 多機能性抗体
US20240181073A1 (en) 2021-03-03 2024-06-06 Sorrento Therapeutics, Inc. Antibody-Drug Conjugates Comprising an Anti-BCMA Antibody
CN116897149A (zh) * 2021-03-30 2023-10-17 上海复旦张江生物医药股份有限公司 一种连接基药物偶联物的制备方法及其中间体
JP2024526764A (ja) 2021-07-13 2024-07-19 トゥルーバインディング，インコーポレイテッド タンパク質凝集を防止する方法
CN118265544A (zh) 2021-09-16 2024-06-28 艾维迪提生物科学公司 治疗面肩肱型肌营养不良的组合物和方法
CN118524852A (zh) 2021-11-09 2024-08-20 真和制药有限公司 治疗或抑制心血管疾病的方法
AU2022422149A1 (en) 2021-12-23 2024-08-01 Mirecule, Inc. Compositions for delivery of polynucleotides
EP4489790A1 (en) 2022-03-10 2025-01-15 Vivasor, Inc. Antibody-drug conjugates and uses thereof
US12071621B2 (en) 2022-04-05 2024-08-27 Avidity Biosciences, Inc. Anti-transferrin receptor antibody-PMO conjugates for inducing DMD exon 44 skipping
CN120659627A (zh) 2022-07-29 2025-09-16 瑞泽恩制药公司 用于转铁蛋白受体（tfr）介导的脑和肌肉递送的组合物和方法
CN119997985A (zh) 2022-08-15 2025-05-13 西纳福克斯股份有限公司 蒽环类药物及其缀合物
WO2024067841A1 (zh) 2022-09-30 2024-04-04 上海迪诺医药科技有限公司 苯并氮杂卓衍生物、含其的偶联物及其应用
KR20250116795A (ko) 2022-11-14 2025-08-01 리제너론 파마슈티칼스 인코포레이티드 별아교세포로의 섬유아세포 성장 인자 수용체 3-매개된 전달을 위한 조성물 및 방법
EP4389152A1 (en) 2022-12-23 2024-06-26 Synaffix B.V. Conjugates of pbd prodrugs
CN116621927B (zh) * 2023-01-09 2024-03-26 联宁（苏州）生物制药有限公司 带有伊喜替康和C-lock定点偶联基团的抗体偶联中间体、偶联方法及抗体偶联药物
EP4410313A1 (en) 2023-01-31 2024-08-07 Synaffix B.V. Homogeneous antibody-conjugates with high payload loading
CN121969397A (zh) 2023-04-05 2026-05-01 维硕公司 抗体偶联药物及其用途
WO2024211235A1 (en) 2023-04-05 2024-10-10 Sorrento Therapeutics, Inc. Antibody-drug conjugates and uses thereof
CN121969398A (zh) 2023-04-05 2026-05-01 维硕公司 抗体偶联药物及其用途
WO2024218164A1 (en) 2023-04-17 2024-10-24 Synaffix B.V. Stable 4-isoxazoline conjugates
EP4450093A1 (en) 2023-04-17 2024-10-23 Synaffix B.V. Cleavable immune cell engagers
EP4735602A2 (en) 2023-06-27 2026-05-06 Atrium Therapeutics, Inc. Compositions and methods of using prkag2-targeting antibody-oligonucleotide conjugates abstract
AU2024308906A1 (en) 2023-06-30 2026-02-05 Atrium Therapeutics, Inc. Compositions and methods of using pln-targeting antibody-oligonucleotide conjugates
WO2025027529A1 (en) 2023-07-31 2025-02-06 Advesya Anti-il-1rap antibody drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗ｉｌ－１ｒａｐ結合結構域及其抗體－藥物偶聯物
CN117964682A (zh) * 2024-01-12 2024-05-03 杭州爱科瑞思生物医药有限公司 Dolastatin衍生物及其制备方法和应用
WO2025238253A1 (en) 2024-05-16 2025-11-20 Synaffix B.V. Antibody-oligonucleotide conjugates
WO2026008881A1 (en) 2024-07-05 2026-01-08 Synaffix B.V. Extracellular vesicles comprising biomolecule-conjugates
US20260078179A1 (en) 2024-07-18 2026-03-19 Novarock Biotherapeutics, Ltd. Cdh17 antibodies and uses thereof

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005297A1 (en) 1986-03-03 1987-09-11 The University Of Chicago Cephalosporin derivatives
EP0624377A2 (en) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Lysosomal enzyme-cleavable antitumor drug conjugates
WO2005081711A2 (en) * 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2007146695A1 (en) 2006-06-06 2007-12-21 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis c protease inhibitors
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
US8435528B2 (en) 2003-05-20 2013-05-07 Immunogen, Inc. Cytotoxic agents comprising new maytansinoids

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6569834B1 (en) 1992-12-03 2003-05-27 George R. Pettit Elucidation and synthesis of antineoplastic tetrapeptide w-aminoalkyl-amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
EP0731106B1 (en) 1993-10-01 2004-11-17 Teikoku Hormone Mfg. Co., Ltd. Dolastatin derivatives
US5525474A (en) * 1994-01-31 1996-06-11 Boehringer Mannheim Corporation Piperidine analogs and conjugates of procainamide and NAPA
CA2427146A1 (en) 2000-10-25 2002-07-18 Mayo Foundation For Medical Education And Research Transcobalamin binding conjugates useful for treating abnormal cellular proliferation
US7771727B2 (en) * 2002-03-01 2010-08-10 The Administrators Of The Tulane Educational Fund Conjugates of therapeutic or cytotoxic agents and biologically active peptides
US20090068178A1 (en) 2002-05-08 2009-03-12 Genentech, Inc. Compositions and Methods for the Treatment of Tumor of Hematopoietic Origin
DK1523493T3 (da) 2002-07-09 2013-12-02 Alexander Doemling Nye tubulysinanaloge
DK1545613T3 (da) 2002-07-31 2011-11-14 Seattle Genetics Inc Auristatinkonjugater og deres anvendelse til behandling af cancer, en autoimmun sygdom eller en infektiøs sygdom
DE10254439A1 (de) 2002-11-21 2004-06-03 GESELLSCHAFT FüR BIOTECHNOLOGISCHE FORSCHUNG MBH (GBF) Tubulysine, Herstellungsverfahren und Tubulysin-Mittel
CN101087611B (zh) * 2003-10-10 2019-04-23 伊缪诺金公司 用经不可切割接头连接的细胞结合剂美登木素生物碱偶联物靶向特定细胞群的方法、所述偶联物和制备所述偶联物的方法
DK1791565T3 (en) 2004-09-23 2016-08-01 Genentech Inc Cysteingensplejsede antibodies and conjugates
JP4993645B2 (ja) * 2004-12-01 2012-08-08 ジェネンテック， インコーポレイテッド 抗体薬剤結合体および方法
US20070134243A1 (en) 2004-12-01 2007-06-14 Gazzard Lewis J Antibody drug conjugates and methods
JP2008537673A (ja) * 2005-01-31 2008-09-25 ジェネンテック・インコーポレーテッド 抗ｅｐｈｂ２抗体とその使用方法
DK3248613T3 (da) * 2005-07-18 2022-03-14 Seagen Inc Beta-glucuronid-lægemiddel-linkerkonjugater
EP2354163A3 (en) * 2005-09-26 2013-04-24 Medarex, Inc. Conjugates of duocarmycin and anti-CD70 or anti-PSMA antibodies
AR059900A1 (es) 2006-03-17 2008-05-07 Genentech Inc Anticuerpos anti-tat226 e inmunoconjugados
EP2056709A4 (en) * 2006-08-11 2013-05-01 Univ New Jersey Med DOUBLE-SENSITIZER WITH LUMINESCENCE COMPOUNDS, CONJUGATES AND USE
CN101500548A (zh) * 2006-08-18 2009-08-05 弗·哈夫曼-拉罗切有限公司 用于体内递送多核苷酸的多缀合物
AU2008224988A1 (en) 2007-03-14 2008-09-18 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
WO2008128164A1 (en) 2007-04-12 2008-10-23 The Penn State Research Foundation Accumulation field effect microelectronic device and process for the formation thereof
CN101784565B (zh) * 2007-06-25 2014-12-10 恩多塞特公司 含有亲水性间隔区接头的共轭物
EP2181101A2 (en) * 2007-07-20 2010-05-05 Helmholtz-Zentrum für Infektionsforschung GmbH Tubulysin d analogues
AU2009270988A1 (en) 2008-07-15 2010-01-21 Genentech, Inc. Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
ES3029483T3 (en) * 2008-09-17 2025-06-24 Endocyte Inc Folate receptor binding conjugates of antifolates
EP2174947A1 (en) 2008-09-25 2010-04-14 Universität des Saarlandes Bioactive pre-tubulysins and use thereof
WO2010081004A1 (en) * 2009-01-09 2010-07-15 Seattle Genetics, Inc. Weekly dosing regimens for anti-cd30 vc-pab-mmae antibody drug-conjugates
EP2403538B1 (en) 2009-03-04 2017-10-04 Polytherics Limited Conjugated proteins and peptides
US8394922B2 (en) * 2009-08-03 2013-03-12 Medarex, Inc. Antiproliferative compounds, conjugates thereof, methods therefor, and uses thereof
CN102844045A (zh) * 2010-02-08 2012-12-26 艾更斯司股份有限公司 结合于161p2f10b蛋白的抗体药物偶联物(adc)
NZ701208A (en) * 2010-06-03 2016-05-27 Genentech Inc Immuno-pet imaging of antibodies and immunoconjugates and uses thereof
CA2799540A1 (en) 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
EP2409983A1 (en) 2010-07-19 2012-01-25 Leibniz-Institut für Pflanzenbiochemie (IPB) Tubulysin analogues
JP5933562B2 (ja) 2010-09-29 2016-06-15 シアトル ジェネティックス， インコーポレイテッド Ｎ−カルボキシアルキル−アウリスタチンおよびその使用
KR101897307B1 (ko) 2010-12-02 2018-09-10 네르비아노 메디칼 사이언시스 에스.알.엘. 모르폴리닐 안트라사이클린 유도체의 제조 방법
CN110078789A (zh) 2011-05-27 2019-08-02 Ambrx 公司 含有非天然氨基酸连接的海兔毒素衍生物的组合物、涉及该海兔毒素衍生物的方法及其用途
KR102356286B1 (ko) 2011-05-27 2022-02-08 암브룩스, 인코포레이티드 비-천연 아미노산 연결된 돌라스타틴 유도체를 함유하는 조성물, 이를 수반하는 방법, 및 용도
US8815226B2 (en) 2011-06-10 2014-08-26 Mersana Therapeutics, Inc. Protein-polymer-drug conjugates
JP6209159B2 (ja) 2011-06-21 2017-10-04 イミュノジェン・インコーポレーテッド ペプチドリンカーを有する新規メイタンシノイド誘導体およびその結合体
RU2014124984A (ru) 2011-12-05 2016-01-27 Идженика Биотерапьютикс, Инк. Конъюгаты антитело-лекарственное средство и родственные соединения, композиции и способы
CN104640572B (zh) 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物，偶联方法，及其用途
CN108727466B (zh) 2012-06-07 2023-04-28 Ambrx公司 前列腺特异性膜抗原抗体药物结合物
KR102190832B1 (ko) 2012-06-19 2020-12-15 암브룩스, 인코포레이티드 항cd70 항체 약물 컨쥬게이트
CN104411337A (zh) 2012-07-09 2015-03-11 基因泰克公司 包含抗cd79b抗体的免疫偶联物
AU2014337317A1 (en) * 2013-10-15 2016-09-15 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
EP3250238B1 (en) 2015-01-28 2022-06-01 Sorrento Therapeutics, Inc. Antibody drug conjugates
US20170224835A1 (en) 2015-02-06 2017-08-10 Sorrento Therapeutics, Inc. Antibody Drug Conjugates

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987005297A1 (en) 1986-03-03 1987-09-11 The University Of Chicago Cephalosporin derivatives
EP0624377A2 (en) * 1993-05-14 1994-11-17 Bristol-Myers Squibb Company Lysosomal enzyme-cleavable antitumor drug conjugates
US8435528B2 (en) 2003-05-20 2013-05-07 Immunogen, Inc. Cytotoxic agents comprising new maytansinoids
US8088387B2 (en) * 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005081711A2 (en) * 2003-11-06 2005-09-09 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
WO2007146695A1 (en) 2006-06-06 2007-12-21 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis c protease inhibitors

Non-Patent Citations (14)

* Cited by examiner, † Cited by third party
Title
"Handbook of Reagents for Organic Synthesis: Activating Agents and Protecting Groups", 1999, WILEY, pages: 370 - 373
BECKWITH, A. L. J.: "Synthesis of Amides", 1970, INTERSCIENCE, article "The Chemistry of Amides", pages: 105 - 109
BIOCONJUGATE CHEM., vol. 13, 2002, pages 855 - 859
CHEM COMMUNICATIONS, vol. 1, 1998, pages 25 - 26
EISENBERG ET AL., J. MOL. BIOL., vol. 179, 1984, pages 125 - 142
EISENBERG, J. MOL. BIOL., vol. 179, 1984, pages 125 - 142
JANTHUR ET AL.: "Drug Conjugates Such as Antibody Drug Conjugates (ADCs), Immunotoxins and Immunoliposomes Challenge Daily Clinical Practice", INT. J. MOL. SCI., vol. 13, 2012, pages 16020 - 16045
LAURENT DUCRY ET AL.: "Antibody 0 Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies", BIOCONJUGATE CHEMISTRY, vol. 21, no. 1, 2010, pages 5 - 13, XP055000588 *
LLOYD-WILLIAMS, P.; ALBERICIO, F.; GIRALT, E.: "Chemical approaches to the synthesis of peptide and proteins", 1997, CRC PRESS
M BODANSKY: "Peptide chemistry: A practical textbook", 1988, SPRINGER-VERLAG
M. BODANSKY; A. BODANSKY: "The practice of peptide synthesis", SPRINGER-VERLAG
See also references of EP2850059A4
TETRAHEDRON, vol. 61, 2005, pages 10827 - 10852
TRAIL, PA: "Antibody Drug Conjugates as Cancer Therapeutics", ANTIBODIES, vol. 2, 2013, pages 113 - 129, XP002725437, DOI: doi:10.3390/antib2010113

Cited By (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10647676B2 (en) 2004-07-23 2020-05-12 Endocyte, Inc. Bivalent linkers and conjugates thereof
US9555139B2 (en) 2007-03-14 2017-01-31 Endocyte, Inc. Binding ligand linked drug delivery conjugates of tubulysins
US10738086B2 (en) 2007-06-25 2020-08-11 Endocyte Inc. Conjugates containing hydrophilic spacer linkers
US10500204B2 (en) 2007-06-25 2019-12-10 Endocyte, Inc. Vitamin receptor drug delivery conjugates for treating inflammation
US12485179B2 (en) 2012-02-24 2025-12-02 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US11344623B2 (en) 2012-02-24 2022-05-31 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US10080805B2 (en) 2012-02-24 2018-09-25 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US10765756B2 (en) 2012-02-24 2020-09-08 Purdue Research Foundation Cholecystokinin B receptor targeting for imaging and therapy
US9505747B2 (en) 2012-03-29 2016-11-29 Endocyte, Inc. Processes for preparing tubulysin derivatives and conjugates thereof
US9884127B2 (en) 2012-05-15 2018-02-06 Concortis Biosystems, Corp. Drug-conjugates, conjugation methods, and uses thereof
US10967071B2 (en) 2012-05-15 2021-04-06 Concortis Biosystems, Corp. Drug-conjugates, conjugation methods, and uses thereof
US9981046B2 (en) 2012-05-15 2018-05-29 Concortis Biosystems, Corp., a wholly owned Subsidiary of Sorrento Therapeutics, Inc. Drug-conjugates, conjugation methods, and uses thereof
US12115228B2 (en) 2012-05-15 2024-10-15 Concortis Biosystems, Corp. Drug-conjugates, conjugation methods, and uses thereof
US9801951B2 (en) 2012-05-15 2017-10-31 Concortis Biosystems, Corp. Drug-conjugates, conjugation methods, and uses thereof
US9662402B2 (en) 2012-10-16 2017-05-30 Endocyte, Inc. Drug delivery conjugates containing unnatural amino acids and methods for using
US9943610B2 (en) 2012-12-21 2018-04-17 Bioalliance C.V. Hydrophilic self-immolative linkers and conjugates thereof
US12303544B2 (en) 2013-03-15 2025-05-20 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10201614B2 (en) 2013-03-15 2019-02-12 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US11617777B2 (en) 2013-03-15 2023-04-04 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US9522876B2 (en) 2013-03-15 2016-12-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10017460B2 (en) 2013-06-12 2018-07-10 Organolinx Corp. Compounds for promoting liposomal and cellular adhesion and compositions and methods of use thereof
WO2015057876A1 (en) 2013-10-15 2015-04-23 Sorrento Therapeutics Inc. Drug-conjugates with a targeting molecule and two different drugs
US11987622B2 (en) 2013-10-15 2024-05-21 Vivasor, Inc. Drug-conjugates with a targeting molecule and two different drugs
US10836821B2 (en) 2013-10-15 2020-11-17 Sorrento Therapeutics, Inc. Drug-conjugates with a targeting molecule and two different drugs
US11103593B2 (en) 2013-10-15 2021-08-31 Seagen Inc. Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
US10675355B2 (en) 2013-12-27 2020-06-09 Var2 Pharmaceuticals Aps VAR2CSA-drug conjugates
WO2015095953A1 (en) 2013-12-27 2015-07-02 The Centre For Drug Research And Development Sulfonamide-containing linkage systems for drug conjugates
US11560422B2 (en) 2013-12-27 2023-01-24 Zymeworks Inc. Sulfonamide-containing linkage systems for drug conjugates
US9950077B2 (en) 2014-06-20 2018-04-24 Bioalliance C.V. Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof
EP3763738A1 (en) 2014-07-11 2021-01-13 Genmab A/S Antibodies binding axl
WO2016005593A1 (en) 2014-07-11 2016-01-14 Genmab A/S Antibodies binding axl
JP2018138620A (ja) * 2014-09-11 2018-09-06 シアトル ジェネティックス， インコーポレイテッド 第３級アミン含有薬物物質の標的送達
JP2017530100A (ja) * 2014-09-11 2017-10-12 シアトル ジェネティックス， インコーポレイテッド 第３級アミン含有薬物物質の標的送達
EP3194421A4 (en) * 2014-09-17 2018-06-06 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10414822B2 (en) 2014-09-17 2019-09-17 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
EP4029873A1 (en) * 2014-09-17 2022-07-20 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10450378B2 (en) 2014-09-17 2019-10-22 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
KR102494557B1 (ko) 2014-09-17 2023-02-02 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
KR20230020018A (ko) * 2014-09-17 2023-02-09 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
US11591405B2 (en) 2014-09-17 2023-02-28 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
KR102609034B1 (ko) 2014-09-17 2023-12-01 자임워크스 비씨 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
US9879086B2 (en) 2014-09-17 2018-01-30 Zymeworks Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US12152083B2 (en) 2014-09-17 2024-11-26 Zymeworks Bc Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
KR20170069227A (ko) * 2014-09-17 2017-06-20 자임워크스 인코포레이티드 세포독성 및 항유사분열성 화합물, 그리고 이를 이용하는 방법
WO2016041082A1 (en) 2014-09-17 2016-03-24 CDRD Ventures, Inc. Cytotoxic and anti-mitotic compounds, and methods of using the same
US10835616B2 (en) 2014-10-14 2020-11-17 Polytherics Limited Process for the conjugation of a peptide or protein with a reagent comprising a leaving group including a portion of PEG
US9968683B2 (en) 2014-12-17 2018-05-15 Organolinx Corp. Method for conjugating molecules
JP2018512376A (ja) * 2015-01-28 2018-05-17 ソレント・セラピューティクス・インコーポレイテッドＳｏｒｒｅｎｔｏ Ｔｈｅｒａｐｅｕｔｉｃｓ， Ｉｎｃ． 抗体薬物コンジュゲート
EP3250238A4 (en) * 2015-01-28 2018-09-19 Sorrento Therapeutics, Inc. Antibody drug conjugates
US20170190736A1 (en) * 2015-01-28 2017-07-06 Sorrento Therapeutics, Inc. Antibody Drug Conjugates
US10590165B2 (en) 2015-01-28 2020-03-17 Sorrento Therapeutics, Inc. Antibody drug conjugates
CN107849090A (zh) * 2015-01-28 2018-03-27 索伦托医疗有限公司 抗体药物偶联物
EP4137159A1 (en) * 2015-01-28 2023-02-22 Sorrento Therapeutics, Inc. Antibody drug conjugates
EP3253212A4 (en) * 2015-02-06 2018-09-19 Sorrento Therapeutics, Inc. Antibody drug conjugates
WO2017009258A1 (en) 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
EP3730520A1 (en) 2015-07-10 2020-10-28 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
KR102800360B1 (ko) * 2015-11-23 2025-04-23 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-ErbB2 항체-약물 접합체 및 그 조성물, 제조 방법 및 용도
US11903948B2 (en) * 2015-11-23 2024-02-20 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-ErbB2 antibody-drug conjugate and composition thereof, preparation method therefor, and use thereof
US20190076438A1 (en) * 2015-11-23 2019-03-14 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Anti-erbb2 antibody-drug conjugate and composition thereof, preparation method therefor, and application thereof
JP2019502650A (ja) * 2015-11-23 2019-01-31 シチュアン ケルン−バイオテック バイオファーマシューティカル カンパニー リミテッド 抗ＥｒｂＢ２抗体−薬物コンジュゲート及びその組成物、そのための調製方法、並びにその適用
KR20180080128A (ko) * 2015-11-23 2018-07-11 쓰촨 케룬-바이오테크 바이오파마수티컬 컴퍼니 리미티드 항-ErbB2 항체-약물 접합체 및 그 조성물, 제조 방법 및 용도
US11229708B2 (en) 2015-12-04 2022-01-25 Seagen Inc. Conjugates of quaternized tubulysin compounds
US11793880B2 (en) 2015-12-04 2023-10-24 Seagen Inc. Conjugates of quaternized tubulysin compounds
US10472422B2 (en) 2016-01-08 2019-11-12 Abgenomics International Inc. Tetravalent anti-PSGL-1 antibodies and uses thereof
WO2017121877A1 (en) 2016-01-13 2017-07-20 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
EP3412315A4 (en) * 2016-02-04 2019-09-11 Zhejiang Zova Biotherapeutics Inc. ANTI-HER2 ANTIBODY ACTIVE CONJUGATE AND ITS USE
US12318455B2 (en) 2016-02-04 2025-06-03 Hangzhou Adcoris Biopharma Co., Ltd. Anti-HER2 antibody-drug conjugate and application thereof
US11844839B2 (en) 2016-03-25 2023-12-19 Seagen Inc. Process for the preparation of pegylated drug-linkers and intermediates thereof
EP3471771A4 (en) * 2016-05-31 2020-04-15 Sorrento Therapeutics, Inc. ANTIBODY-MEDICINE CONJUGATES WITH DERIVATIVES OF AMATOXIN AS A MEDICINAL PRODUCT
US10111966B2 (en) 2016-06-17 2018-10-30 Magenta Therapeutics, Inc. Methods for the depletion of CD117+ cells
US10517958B2 (en) 2016-10-04 2019-12-31 Zymeworks Inc. Compositions and methods for the treatment of platinum-drug resistant cancer
US10576161B2 (en) 2017-01-20 2020-03-03 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US10434185B2 (en) 2017-01-20 2019-10-08 Magenta Therapeutics, Inc. Compositions and methods for the depletion of CD137+ cells
US11730822B2 (en) 2017-03-24 2023-08-22 Seagen Inc. Process for the preparation of glucuronide drug-linkers and intermediates thereof
US11389543B2 (en) 2017-09-08 2022-07-19 Seagen Inc. Process for the preparation of tubulysins and intermediates thereof
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
WO2022197945A1 (en) 2021-03-17 2022-09-22 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
WO2024179381A1 (zh) 2023-02-28 2024-09-06 四川科伦博泰生物医药股份有限公司 一类化学偶联连接子及其用途

Also Published As

Publication number Publication date
JP6239598B2 (ja) 2017-11-29
US12115228B2 (en) 2024-10-15
EP3590541A1 (en) 2020-01-08
JP2015518831A (ja) 2015-07-06
US10967071B2 (en) 2021-04-06
EP2849790B1 (en) 2019-04-10
WO2013173391A1 (en) 2013-11-21
US20150105539A1 (en) 2015-04-16
US20150141646A1 (en) 2015-05-21
EP2849797A1 (en) 2015-03-25
CN104640572B (zh) 2018-04-27
EP3925627A1 (en) 2021-12-22
US9884127B2 (en) 2018-02-06
CN104662000A (zh) 2015-05-27
HK1208163A1 (en) 2016-02-26
CN107982545A (zh) 2018-05-04
CN104662000B (zh) 2018-08-17
CN104640572A (zh) 2015-05-20
CN104379168B (zh) 2017-08-15
EP2850059A4 (en) 2016-06-29
ES2887208T3 (es) 2021-12-22
US20180243438A1 (en) 2018-08-30
US20160067350A1 (en) 2016-03-10
US20250135024A1 (en) 2025-05-01
US9801951B2 (en) 2017-10-31
CN107982545B (zh) 2021-04-09
EP3590541B1 (en) 2021-08-11
EP2849797B1 (en) 2019-12-18
EP2849790A4 (en) 2016-04-13
ES2734259T3 (es) 2019-12-05
EP3520817A1 (en) 2019-08-07
EP2850059A1 (en) 2015-03-25
JP2015518832A (ja) 2015-07-06
EP2849790A1 (en) 2015-03-25
HK1208165A1 (en) 2016-04-01
US9981046B2 (en) 2018-05-29
JP6239597B2 (ja) 2017-11-29
JP2018052951A (ja) 2018-04-05
US20180085471A1 (en) 2018-03-29
JP2018058851A (ja) 2018-04-12
EP2849797A4 (en) 2016-04-27
HK1208216A1 (en) 2016-02-26
JP6280103B2 (ja) 2018-02-14
JP2015518833A (ja) 2015-07-06
US20210187119A1 (en) 2021-06-24
CN104379168A (zh) 2015-02-25
WO2013173393A1 (en) 2013-11-21

Similar Documents

Publication Publication Date Title
US9981046B2 (en) Drug-conjugates, conjugation methods, and uses thereof
EP3057610B1 (en) Drug-conjugates with a targeting molecule and two different drugs
US10722593B2 (en) Anti-cancer compounds and conjugates thereof
HK40012657A (en) Drug-conjugates, conjugation methods, and uses thereof
HK40064991A (en) Drug-conjugates and uses thereof
HK40011591A (en) Drug-conjugates and uses thereof
HK40011591B (en) Drug-conjugates and uses thereof
HK1208165B (en) Drug-conjugates, conjugation methods, and uses thereof
HK1208163B (en) Drug-conjugates, conjugation methods, and uses thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13790777

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 14401115

Country of ref document: US

ENP Entry into the national phase

Ref document number: 2015512770

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2013790777

Country of ref document: EP